The clinical relevance of MCM3 levels was demonstrated by its strong correlation with RFS and OS in 4 independent cohorts consisting of 79, 218, 2305, and 683 early-stage, ER+ breast cancer patients receiving adjuvant tamoxifen or no adjuvant treatment. The gene discussed is MCM3; the disease is breast carcinoma.